Screening for modulators of cisplatin sensitivity: Unbiased screens reveal common themes

Cell Cycle

Volumn 10, Issue 3, 2011, Pages 380-386

  Nijwening, Jeroen H ^a   Kuiken, Hendrik J ^a   Beijersbergen, Roderick L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; DDR; RNAi; Screen; Sensitivity

Indexed keywords

ATR PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN;

APOPTOSIS; CELL CYCLE ARREST; CONFORMATIONAL TRANSITION; DNA ADDUCT; DNA DAMAGE; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; EXCISION REPAIR; GENE IDENTIFICATION; HOMOLOGOUS RECOMBINATION; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; REVIEW; SOLID TUMOR; VALIDATION PROCESS;

EID: 79851493302     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.3.14642     Document Type: Review

References (37)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-84. (Pubitemid 47106628)
2. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15:3-11. (Pubitemid 40696471)
3. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle 2008; 7:1353-9.
4. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23. (Pubitemid 46137553)
5. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 2010; 7:543-66.
6. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007; 6:2344-7.
7. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179-204.
8. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899-902. (Pubitemid 34984411)
9. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-74. (Pubitemid 32467046)
10. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79. (Pubitemid 37487159)
11. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, et al. The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58:3579-85. (Pubitemid 28376554)
12. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 2003; 98:2199-206. (Pubitemid 37392424)
13. He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000; 97:5768-72. (Pubitemid 30367473)
14. Wu F, Lin X, Okuda T, Howell SB. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity and the rate of development of cisplatin resistance. Cancer Res 2004; 64:8029-35. (Pubitemid 39446939)
15. Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, Gueranger Q, et al. Differential roles for DNA polymerases eta, zeta and REV1 in lesion bypass of intrastrand versus interstrand DNA crosslinks. Mol Cell Biol 2010; 30:1217-30.
16. Livneh Z. Keeping mammalian mutation load in check: regulation of the activity of error-prone DNA polymerases by p53 and p21. Cell Cycle 2006; 5:1918-22. (Pubitemid 44435294)
17. Scharer OD. DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses. Chembiochem 2005; 6:27-32. (Pubitemid 40128631)
18. Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, et al. Cisplatin sensitivity of testis tumor cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010; 9:248.
19. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009; 43:223-49.
20. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6:556-68. (Pubitemid 47019444)
21. Bernards R. It's diagnostics, stupid. Cell 2010; 141:13-7.
22. Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000; 60:328-33. (Pubitemid 30070759)
23. Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin and mitomycin C. Cancer Res 2004; 64:3940-8. (Pubitemid 38697308)
24. Dronkert ML, de Wit J, Boeve M, Vasconcelos ML, van Steeg H, Tan TL, et al. Disruption of mouse SNM1 causes increased sensitivity to the DNA interstrand crosslinking agent mitomycin C. Mol Cell Biol 2000; 20:4553-61. (Pubitemid 30396103)
25. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004; 116:121-37. (Pubitemid 38156189)
26. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and Tp53 disruptions. Mol Cell Biol 2006; 26:9377-86. (Pubitemid 44904431)
27. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, et al. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol 2010; 118:220-7.
28. Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, et al. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 2008; 7:800-8. (Pubitemid 351551033)
29. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004; 206:169-80. (Pubitemid 38317287)
30. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11:498-512. (Pubitemid 46856907)
31. Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, et al. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci USA 2010; 107:20786-91.
32. Sharma S, Freeman B, Turner J, Symanowski J, Manno P, Berg W, et al. A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Invest New Drugs 2009; 27:63-5.
33. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-9.
34. Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA damage response - an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009; 625:143-50.
35. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97:2187-95. (Pubitemid 36444059)
36. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005; 104:1004-12. (Pubitemid 41170228)
37. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003; 2:290-2.